IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies

Several studies have identified mutations in the MYD88L265P gene as a key driver mutation in several B-cell lymphomas. B-cell lymphomas that harbor the MYD88L265P mutation form a complex with phosphorylated Bruton’s tyrosine kinase (BTK) and are responsive to BTK inhibition. However, BTK inhibition...

Full description

Bibliographic Details
Main Authors: Ricardo D. Parrondo, Madiha Iqbal, Reinhard Von Roemeling, Christina Von Roemeling, Han W. Tun
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
non-Hodgkin lymphoma
myeloid malignancies
TLR signaling
IRAK 4
small molecule inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1239082/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1239082/full

Similar Items